Per Norlén

Dr Per Norlén brings over two decades of experience in clinical drug development and biotech leadership. He has held senior roles at AstraZeneca and several private and publicly listed companies, including Alligator Bioscience, Targinta, Evaxion Biotech, and WntResearch. He is currently CEO of Strike Pharma. His expertise supports Xinnate’s continued growth in developing advanced treatments for inflammatory skin diseases.